ATE555656T1 - Verwendung von seh-hemmern als analgetika - Google Patents

Verwendung von seh-hemmern als analgetika

Info

Publication number
ATE555656T1
ATE555656T1 AT06813607T AT06813607T ATE555656T1 AT E555656 T1 ATE555656 T1 AT E555656T1 AT 06813607 T AT06813607 T AT 06813607T AT 06813607 T AT06813607 T AT 06813607T AT E555656 T1 ATE555656 T1 AT E555656T1
Authority
AT
Austria
Prior art keywords
analgesics
vision
inhibitors
reducing
eet
Prior art date
Application number
AT06813607T
Other languages
English (en)
Inventor
Bruce Hammock
Ahmet Bora Inceoglu
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE555656T1 publication Critical patent/ATE555656T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT06813607T 2005-08-19 2006-08-18 Verwendung von seh-hemmern als analgetika ATE555656T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70974105P 2005-08-19 2005-08-19
PCT/US2006/032595 WO2007022509A2 (en) 2005-08-19 2006-08-18 Use of seh inhibitors as analgesics

Publications (1)

Publication Number Publication Date
ATE555656T1 true ATE555656T1 (de) 2012-05-15

Family

ID=37758492

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06813607T ATE555656T1 (de) 2005-08-19 2006-08-18 Verwendung von seh-hemmern als analgetika

Country Status (6)

Country Link
US (1) US9119837B2 (de)
EP (1) EP1931201B1 (de)
JP (1) JP2009504785A (de)
AT (1) ATE555656T1 (de)
CA (1) CA2619768A1 (de)
WO (1) WO2007022509A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1845976A4 (de) * 2005-01-10 2010-10-27 Univ California Verwendung von hemmern löslicher epoxidhydrolase zur synergierung der aktivität von cox- und 5-lox-hemmern
US8399425B2 (en) 2007-11-08 2013-03-19 The Regents Of The University Of California Alleviating neuropathic pain with EETs and sEH inhibitors
US20110230504A1 (en) * 2008-09-15 2011-09-22 The Regents Of The University Of California Office Of Technology ALLEVIATING DISORDERS WITH COMBINING AGENTS THAT INCREASE EPOXYGENATED FATTY ACIDS AND AGENTS THAT INCREASE cAMP
AU2010229872A1 (en) 2009-03-26 2011-11-03 The Regents Of The University Of California Mesenchymal stem cells producing inhibitory RNA for disease modification
US20110065756A1 (en) * 2009-09-17 2011-03-17 De Taeye Bart M Methods and compositions for treatment of obesity-related diseases
US20120315283A1 (en) * 2010-02-02 2012-12-13 Dana-Farber Cancer Institute, Inc. Methods of promoting tissue growth and tissue regeneration
WO2011130716A2 (en) 2010-04-16 2011-10-20 Access Pharmaceuticals, Inc. A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers
WO2011143607A1 (en) * 2010-05-14 2011-11-17 The Regents Of The University Of California Modulation of bioactive epoxy-fatty acid levels by phosphodiesterase inhibitors
WO2012122313A2 (en) 2011-03-08 2012-09-13 Access Pharmaceuticals, Inc. Targeted nanocarrier systems for delivery of actives across biological membranes
EP2846825B1 (de) * 2012-03-14 2021-05-05 The Regents of The University of California Behandlung von entzündlichen erkrankungen bei nichtmenschlichen säugern
WO2014100602A1 (en) 2012-12-20 2014-06-26 Hospital For Special Surgery Treatment of egf-receptor dependent pathologies
EP3049085B9 (de) 2013-09-26 2021-08-18 Beth Israel Deaconess Medical Center, Inc. Sgk1 inhibitoren bei der behandlung von long-qt-syndrom
WO2016133788A1 (en) 2015-02-20 2016-08-25 The Regents Of The University Of California Methods of inhibiting pain

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4310525A (en) * 1981-01-23 1982-01-12 Nelson Research & Development Company Method of treatment of inflammation
US5445956A (en) 1993-08-13 1995-08-29 The Regents Of The University Of California Recombinant soluble epoxide hydrolase
US5505949A (en) 1994-10-13 1996-04-09 Benitez; Juan E. Topical treatment for acne
US6531506B1 (en) * 1996-08-13 2003-03-11 Regents Of The University Of California Inhibitors of epoxide hydrolases for the treatment of hypertension
US6150415A (en) * 1996-08-13 2000-11-21 The Regents Of The University Of California Epoxide hydrolase complexes and methods therewith
US5955496A (en) * 1996-08-13 1999-09-21 The Regents Of The University Of California Dihydroxy-oxy-eicosadienoates
US6174695B1 (en) * 1997-08-12 2001-01-16 The Regents Of The University Of California Epoxide hydrolase inhibitor methods
IL124118A (en) * 1998-04-16 2007-09-20 Yissum Res Dev Co Propylisopropyl acetic acid and propylisopropyl acetamide stereoisomers, method for their synthesis and pharmaceutical compositions containing them
WO2000023060A2 (en) 1998-10-20 2000-04-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method of treating immunological disorders mediated by t-lymphocytes
US6422715B2 (en) * 1999-06-11 2002-07-23 Technology Creations, Inc. Apparatus for illuminating a portable electronic or computing device
FR2795645B1 (fr) * 1999-06-30 2001-09-21 Union Pharma Scient Appl Nouvelle association pharmaceutique a activite analgesique
AU2001265186A1 (en) * 2000-05-30 2001-12-11 The Brigham And Women's Hospital, Inc. Use of epoxyeicosatrienoic acids in the treatment of cerebrovascular conditions
CA2449486A1 (en) * 2001-06-29 2003-01-09 Boehringer Ingelheim Pharmaceuticals Inc. Methods of using soluble epoxide hydrolase inhibitors
ES2355472T3 (es) * 2002-05-22 2011-03-28 Amgen Inc. Derivados de aminopirimidina para su uso como ligandos del receptor vaniloide para el tratamiento del dolor.
CA2520763A1 (en) * 2003-04-03 2004-10-21 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
EP1845976A4 (de) * 2005-01-10 2010-10-27 Univ California Verwendung von hemmern löslicher epoxidhydrolase zur synergierung der aktivität von cox- und 5-lox-hemmern

Also Published As

Publication number Publication date
US20080249055A1 (en) 2008-10-09
JP2009504785A (ja) 2009-02-05
US9119837B2 (en) 2015-09-01
EP1931201A2 (de) 2008-06-18
EP1931201B1 (de) 2012-05-02
WO2007022509A3 (en) 2007-06-07
WO2007022509A2 (en) 2007-02-22
CA2619768A1 (en) 2007-02-22
EP1931201A4 (de) 2009-11-11

Similar Documents

Publication Publication Date Title
ATE555656T1 (de) Verwendung von seh-hemmern als analgetika
ATE539751T1 (de) Verwendung von brimonidine zur behandlung von stress assoziierten zuständen
SE0301888D0 (sv) New use VII
MA28909B1 (fr) Quinazolines utiles en tant que modulateurs de canaux ioniques
MX2009004475A (es) Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma.
BRPI0518228B8 (pt) inibidores de cinesina mitótica e uso dos mesmos
TW200505508A (en) Methods of administering a dermatological agent to a subject
NO20060416L (no) Ny anvendelse I
BRPI0510617A (pt) uso de expressão de il-17 para prever inflamação de pele; processos de tratamento
TW200722421A (en) Azole derivatives as inhibitors of lipases and phospholipases
SE0301886D0 (sv) New use V
MY149960A (en) 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamide derivatives as mek inhibitors for the treatment of hyperproliferative diseases
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
ATE332129T1 (de) Behandlung der akne mit lipoxygenase inhibitoren
MY151457A (en) Topical formulation and uses thereof
SG156681A1 (en) Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure
TW200730513A (en) Carbamoylbenzotriazole derivatives as inhibitors of lipases and phospholipases
JO3358B1 (ar) معالجات حساسية العيون
WO2006006167A3 (en) Compositions and methods for dermatological wound healing
MY158428A (en) Topical composition for the treatment of actinic keratosis
ATE445389T1 (de) Liposomale glucocorticoide
ITMI20031311A1 (it) Formulazioni per il trattamento di disturbi artrosici.
RS54140B1 (en) USE OF 24-ORDER
UY27772A1 (es) Inhibidores triariloxiariloxipirimidin-2,4,6- triona de metaloproteinasa.
MY146444A (en) Benzooxazol-2-one derivatives as inhibitors of lipases and phospholipases